Intercept's Ocaliva Seems Headed For Black Box On Liver Injury Risk
Executive Summary
Physician education on dosing also likely as firm hopes to show that serious adverse events in patients with less-advanced primary biliary cholangitis may not be related to the drug.
You may also be interested in...
ICER: Madrigal’s Resmetirom Looks More Cost-Effective In NASH Than Intercept’s OCA
In a draft assessment, the non-profit said Madrigal’s non-alcoholic steatohepatitis candidate might yield cost savings over a lifetime of care. Both drugs seem to offer incremental benefits for survival and quality of life.
Intercept Drug’s Market Standing In PBC Undermined By Safety Woes
A second FDA safety labeling update for Intercept’s Ocaliva might open a market opportunity in second-line PBC for Phase III candidates at CymaBay and Genfit.
Intercept Commits To Resubmitting NASH NDA, But Analysts See Conflicting Signs
CEO Durso says Intercept is aiming to refile its NDA by end of 2021, but several departures in recent months indicate pessimism on NASH prospects to some analysts.